What's in Haisco Pharmaceutical Group Co., Ltd.'s pipeline?

Haisco Pharmaceutical Group Co., Ltd. has 41 drugs in our index: 1 marketed, 0 filed, 5 in Phase 3, 19 in Phase 2, 16 in Phase 1.

Which companies overlap with Haisco Pharmaceutical Group Co., Ltd.'s portfolio?

Top competitors by shared drug class: Bayer, Beta Pharma Shanghai, Betta Pharmaceuticals Co., Ltd., Caliway Biopharmaceuticals Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/haisco-pharmaceutical-group-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Haisco Pharmaceutical Group Co., Ltd. — Portfolio Competitive Intelligence Brief

Haisco Pharmaceutical Group Co., Ltd. pipeline: 1 marketed, 0 filed, 5 Phase 3, 19 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 5 Phase 3 19 Phase 2 16 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Daily DPP-4 inhibitor	Daily DPP-4 inhibitor	marketed
HSK39297 tablets	HSK39297 tablets	phase 3
HSK39297	HSK39297	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology
HL231 Solution for Inhalation	HL231 Solution for Inhalation	phase 3
Acetyllevocarnitine Hydrochloride Tablets	Acetyllevocarnitine Hydrochloride Tablets	phase 3	Metabolic agent / Mitochondrial function enhancer	Carnitine palmitoyltransferase (CPT) system	Neurology / Metabolic disorders
HSK31858, tablet	HSK31858, tablet	phase 3	FGFR inhibitor	FGFR (Fibroblast Growth Factor Receptor)	Oncology

Therapeutic area mix

Oncology · 2
Neurology / Metabolic disorders · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Bayer · 1 shared drug class
Beta Pharma Shanghai · 1 shared drug class
Betta Pharmaceuticals Co., Ltd. · 1 shared drug class
Caliway Biopharmaceuticals Co., Ltd. · 1 shared drug class
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · 1 shared drug class
Eisai Inc. · 1 shared drug class
Eli Lilly and Company · 1 shared drug class
Allist Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Haisco Pharmaceutical Group Co., Ltd.:

Cite this brief

Drug Landscape (2026). Haisco Pharmaceutical Group Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/haisco-pharmaceutical-group-co-ltd. Accessed 2026-05-16.